American Society of Hematology

Fig. 6.

$Fig. 6. Protection of RPMI 8226 myeloma cells against imexon-induced toxicity by treatment with TTFA. / The cells were treated with 180 μM imexon or 50 μM TTFA or both and evaluated for morphologic changes by bright-field microscopy after DiffQuick staining (A, × 100 oil immersion). The untreated cells were included as control. Two hundred cells per slide were evaluated for apoptotic changes. The graph represents the fraction of apoptotic cells in the different treatment groups (B). The star indicates a statistically significant difference as compared to the imexon-treated cells (P < .05).$

Protection of RPMI 8226 myeloma cells against imexon-induced toxicity by treatment with TTFA.

The cells were treated with 180 μM imexon or 50 μM TTFA or both and evaluated for morphologic changes by bright-field microscopy after DiffQuick staining (A, × 100 oil immersion). The untreated cells were included as control. Two hundred cells per slide were evaluated for apoptotic changes. The graph represents the fraction of apoptotic cells in the different treatment groups (B). The star indicates a statistically significant difference as compared to the imexon-treated cells (P < .05).

This Feature Is Available To Subscribers Only